ELEVATION POINT WEALTH PARTNERS, LLC
Position in PTGX — Protagonist Therapeutics, Inc
CIK 1744349
DENVER, CO
Position in PTGX
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$290,392
New position
Shares Held
2,369
first reported quarter
Ownership
0.004%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#248
of 341 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026ELEVATION POINT WEALTH PARTNERS, LLC holds $12,657,390 across 22 Biotechnology names. PTGX ranks #13 (2.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NTLA |
Intellia Therapeutics, Inc.
|
188,207 | $3,184,462 | |
| 2 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
16,991 | $1,384,936 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,252 | $1,118,635 | |
| 4 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
8,902 | $867,766 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,241 | $773,813 | |
| 6 | ABVX |
Abivax S.A.
|
5,256 | $700,414 | |
| 7 | DFTX |
Definium Therapeutics, Inc.
|
11,382 | $535,409 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
|
1,847 | $452,090 |
All Filings in PTGX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $290,392 | 2,369 | Shares | Sole | 2026-08-12 | |
| No filing history on record for this holder in this stock. | ||||||